Comparative Pharmacology
Head-to-head clinical analysis: LAMIVUDINE NEVIRAPINE ZIDOVUDINE TABLETS versus LAMIVUDINE STAVUDINE NEVIRAPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMIVUDINE NEVIRAPINE ZIDOVUDINE TABLETS versus LAMIVUDINE STAVUDINE NEVIRAPINE.
LAMIVUDINE/NEVIRAPINE/ZIDOVUDINE TABLETS vs LAMIVUDINE; STAVUDINE; NEVIRAPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase by competing with natural substrates and causing chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing conformational disruption. Zidovudine is an NRTI that inhibits viral reverse transcriptase after intracellular phosphorylation to its active triphosphate form.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase by competing with natural substrate and causing chain termination. Stavudine is an NRTI that inhibits HIV-1 reverse transcriptase after intracellular phosphorylation to its active triphosphate form. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV-1 reverse transcriptase, causing allosteric inhibition.
One tablet (150 mg lamivudine/200 mg nevirapine/300 mg zidovudine) orally twice daily.
One tablet containing lamivudine 150 mg, stavudine 30 mg (or 40 mg if weight ≥60 kg), and nevirapine 200 mg orally twice daily.
None Documented
None Documented
Lamivudine: 5-7h (adults), prolonged in renal impairment. Nevirapine: 25-30h (single dose), 40-45h (multiple doses, autoinduction). Zidovudine: 0.5-3h (terminal), prolonged in hepatic impairment.
Lamivudine: 5-7 h (prolonged in renal impairment); Stavudine: 1.6 h (prolonged in renal impairment, ~3.5-8 h in ESRD); Nevirapine: ~45 h (single dose), ~25-30 h (multiple doses due to autoinduction; prolonged in hepatic impairment).
Lamivudine: ~70% renal (glomerular filtration and tubular secretion, unchanged). Nevirapine: ~80% biliary/fecal (metabolites), ~10% renal (unchanged). Zidovudine: ~75% renal (metabolism to glucuronide, tubular secretion).
Lamivudine: ~70% renal (glomerular filtration and tubular secretion), ~30% unchanged; Stavudine: ~40% renal (tubular secretion), ~60% metabolized to inactive metabolites; Nevirapine: ~80% renal (metabolites, <5% unchanged), ~10% fecal.
Category A/B
Category A/B
NRTI
NRTI